通常分割照射
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.van As N, Griffin C, Tree A, et al. N Engl J Med. 2024 Oct 17;391(15):1413-1425. DOI: 10.1056/NEJMoa2403365. PMID: 39413377; PMCID: PMC7616714. 【背景】・前立腺が…
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Widmark A, Gunnlaugsson A, Beckman L, et al. Lancet. 2019 Aug 3;394(1…
Hypofractionated Dose Escalation versus Conventionally Fractionated Radiotherapy for Patients with Intermediate- and High-risk Localized Prostate Cancer: Long-term Results of the HYPRO trial.Wiersma RG, de Vries KC, Heemsbergen WD, et al. …
![はてなブックマーク - 【HYPRO：第III相試験 10年成績】限局性前立腺がんに対する寡分割照射（64.6 Gy/19回 [週3回]） vs. 通常分割照射（78 Gy/39回）](https://b.hatena.ne.jp/entry/image/https://uminoshion.hatenablog.com/entry/2025/10/19/104733)
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.van As N, Griffin C, Tree A, et al. N Engl J Med. 2024 Oct 17;391(15):1413-1425. doi: 10.1056/NEJMoa2403365. PMID: 39413377; PMCID: PMC7616714. 【概要】・低リスク…
Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial.Niazi T, Nabid A, Malagon T, et al. Eur Urol. 2025 Mar;87(3):314-323. do…
Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial. Langé M, Campion L, Ollivier L, et al. Int J Radiat Oncol Biol Phys. 2025 Jun 1;122(2):399-406. DOI: 10.1016/j.ijrobp.2025…
